A5038723818- Gastrointestinal Tumor Research and Treatment
- Gastric Cancer Management and Outcomes
- Sarcoma Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Vascular Tumors and Angiosarcomas
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Gastrointestinal disorders and treatments
- Cardiac tumors and thrombi
- Lymphoma Diagnosis and Treatment
- Cancer survivorship and care
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Palliative Care and End-of-Life Issues
- Cancer Genomics and Diagnostics
- Bone Tumor Diagnosis and Treatments
- CAR-T cell therapy research
- Management of metastatic bone disease
- Chronic Myeloid Leukemia Treatments
- Metastasis and carcinoma case studies
- Colorectal and Anal Carcinomas
- Soft tissue tumors and treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Uterine Myomas and Treatments
- Neuroendocrine Tumor Research Advances
Helios Hospital Berlin-Buch
2003-2025
Helios Hospital Bad Saarow
2016-2025
Universitätsmedizin Greifswald
2016-2025
Klinik und Poliklinik für Psychotherapie und Psychosomatik
2020
University Hospital Carl Gustav Carus
2020
Imperial College London
2017
Sahlgrenska University Hospital
2015
Oulu University Hospital
2015
Oslo University Hospital
2015
Massachusetts Institute of Technology
2010
<h3>Context</h3>Adjuvant imatinib administered for 12 months after surgery has improved recurrence-free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared placebo.<h3>Objective</h3>To investigate the role administration duration as adjuvant treatment who have a high estimated risk GIST recurrence surgery.<h3>Design, Setting, and Patients</h3>Patients KIT-positive removed at were entered between February 2004 September 2008 to this randomized, open-label...
Abstract Gastrointestinal stromal tumors (GIST) are characterized by a strong KIT receptor activation most often resulting from mutations. In smaller subgroup of without mutations, analogous activating mutations found in the platelet-derived growth factor α (PDGFRα) gene. Both PDGFRα and receptors targets tyrosine kinase inhibitor imatinib (Glivec) which has improved treatment advanced GISTs significantly. However, show secondary progress under therapy with after initial response. One...
Three years of adjuvant imatinib therapy are recommended for patients with GI stromal tumor (GIST) high-risk features, according to survival findings in the Scandinavian Sarcoma Group XVIII/AIO (Arbeitsgemeinschaft Internistische Onkologie) trial. To investigate whether benefits have persisted, we performed second planned analysis trial.Eligible had macroscopically completely excised, KIT-positive GIST a high risk recurrence, as determined by using modified National Institutes Health...
Little is known about whether the duration of adjuvant imatinib influences prognostic significance KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet-derived growth factor α (PDGFRA) mutations.To investigate effect PDGFRA mutations on recurrence-free survival (RFS) in patients with gastrointestinal stromal tumors (GISTs) treated surgery imatinib.This exploratory study based Scandinavian Sarcoma Group VIII/Arbeitsgemeinschaft Internistische Onkologie (SSGXVIII/AIO) multicenter...
Abstract Background This study assessed the outcomes of patients with a gastrointestinal stromal tumour (GIST) that ruptured before or during resection. Methods The records 23 (8 women, 15 men; median age 54 years) primary non-metastatic GIST were retrieved from database 554 patients. written surgical and pathology reports analysed. Review was performed in all cases, mutational analysis KIT platelet-derived growth factor α (PDGFRA) genes 21 Median follow-up 52 months. Results Tumour rupture...
To determine if diffusion-weighted imaging (DWI) can be used as a surrogate marker of tumor response to anticancer therapy in patients with soft-tissue sarcomas.Magnetic resonance (MRI) including echo-planar DWI sequences was performed prospectively 23 consecutive sarcomas before and after initiation regional or systemic chemotherapy. The mean interval between initial follow-up MRI 56.9 +/- 23.2 days. Tumor volumes were determined by manual segmentation borders on contrast-enhanced...
Background and purpose There have been few long-term studies on the outcome of chondrosarcoma findings regarding prognostic factors are controversial. We examined a homogeneous group patients with primary central bone who were treated according to uniform surgical protocol at our institution, in order determine that influence survival identify potential improvements therapeutic algorithm.Patients methods performed retrospective analysis 115 presented localized disease had minimum follow-up 5...
Pancreatic Ductal Adenocarcinoma (PDAC) is an aggressive malignancy characterised by the presence of extensive desmoplasia, thought to be responsible for poor response patients systemic therapies. stellate cells (PSCs) are key mediators in production this fibrotic stroma, upon activation transitioning a myofibroblast-like, high matrix secreting phenotype. Given their importance disease progression, characterisation PSC has been extensive, however one aspect that overlooked mechano-sensing...
4502 Background: Perioperative FLOT is a standard of care for resectable, esophagogastric adenocarcinoma (EGA). This trial evaluates the addition trastuzumab (tras) and pertuzumab (per) to HER2-positive resectable patients (pts). Methods: PETRARCA prospective, multicenter, randomized, investigator initiated planned as phase II/III investigation. We report II part this trial. Pts with HER2+ EGA (≥ cT2 or cN+) were enrolled. randomized 1:1 4 pre- post-operative cycles (Docetaxel 50 mg/m²;...
PURPOSE High pathologic complete response (pCR) rates and comparably good survival data were seen in a phase II trial combining perioperative fluorouracil, leucovorin, oxaliplatin, docetaxel (FLOT) chemotherapy with trastuzumab for resectable, esophagogastric adenocarcinoma (EGA). The current evaluates the addition of pertuzumab to FLOT as treatment human epidermal growth factor receptor 2–positive resectable EGA. METHODS In this multicenter, randomized II/III trial, patients 2–positive, EGA...
<h3>Importance</h3> In metastatic esophagogastric adenocarcinoma (EGA), the addition of programmed cell death 1 (PD-1) inhibitors to chemotherapy has improved outcomes in selected patient populations. <h3>Objective</h3> To investigate efficacy trastuzumab and PD-1 with cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) or FOLFOX first-line treatment advanced<i>ERBB2</i>-positive EGA. <h3>Design, Setting, Participants</h3> This phase 2 multicenter, outpatient, randomized clinical trial...
The multicenter, randomized, phase IV, intergroup AGO-B WSG PreCycle trial (NCT03220178) evaluated the impact of CANKADO-based electronic patient-reported outcome (ePRO) assessment on quality life (QoL) in hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer (MBC) patients receiving palbociclib and an aromatase inhibitor + fulvestrant. CANKADO PRO-React, a European Union-registered medical device, is interactive autonomous...
Objectives: Angiotensin II (Ang II) induces fibroblast proliferation and collagen synthesis in the myocardium, but its precise mechanisms of action human hearts are still unknown. Therefore, we investigated whether Ang directly affects mRNA content myocardium isolated cardiac fibroblasts or growth factors TGFβ-1 osteopontin involved this process. Methods results I: In a first set experiments, direct effect on I, fresh samples atrial was determined by use short stimulation period. After 4 h,...
Abstract Purpose: To study the safety, tolerability, and pharmacokinetics of selective tyrosine kinase inhibitor nilotinib as a single agent or in combination with imatinib patients advanced imatinib-resistant gastrointestinal stromal tumors. Experimental Design: A phase I intercohort dose-escalation trial was done who received either (a) 400 mg twice daily (b) escalating doses (200 once daily, qd, bid) plus bid (10- 14-hour interval daily), (c) qd. Safety, pharmacokinetics, tumor...
BACKGROUND Little is known about the factors that predict for gastrointestinal stromal tumor (GIST) recurrence in patients treated with adjuvant imatinib. METHODS Risk GIST were identified, and 2 risk stratification scores developed using database of Scandinavian Sarcoma Group (SSG) XVIII trial, where 358 high‐risk no overt metastases randomly assigned to imatinib 400 mg/day either 12 or 36 months after surgery. The findings validated arm American College Surgeons Oncology Z9001 359...
Importance Adding immune checkpoint inhibitors to chemotherapy has been associated with improved outcomes in metastatic esophagogastric adenocarcinoma, but treatment combinations and optimal patient selection need be established. Objective To investigate the efficacy tolerability of programmed cell death ligand 1 (PDL-1) inhibitor avelumab paclitaxel plus ramucirumab. Design, Setting, Participants This multicenter, single-group, phase 2 nonrandomized controlled trial was conducted among...
Objective The ExPRO (External factors influencing patient reported outcomes of patients with malignant diseases) study explored associations between QoL data and environmental on the day questionnaire completion: mean temperature, sunshine hours, season, lunar phase.
Introduction: The impact of being diagnosed with a life-threatening illness may influence preferences to participate in treatment decisions. objective this analysis was identify factors that are associated sarcoma patients wanting take more active or passive role. Methods: Data obtained as part nationwide multicenter study (PROSa) aiming investigate the structure and quality medical care Germany their determinants. conducted between 2017 2020 39 centers. For present analysis, cross-sectional...